Literature DB >> 14592768

Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop.

Robyn L Stanfield1, Jayant B Ghiara, Erica Ollmann Saphire, Albert T Profy, Ian A Wilson.   

Abstract

The crystal structure of the human immunodeficiency virus type 1 (HIV-1) neutralizing, murine Fab 83.1 in complex with an HIV-1 gp120 V3 peptide has been determined to 2.57 A resolution. The conformation of the V3 loop peptide in complex with Fab 83.1 is very similar to V3 conformations seen previously with two other neutralizing Fabs, 50.1 and 59.1. The repeated identification of this same V3 conformation in complex with three very different, neutralizing antibodies indicates that it is a highly preferred structure for V3 loops on some strains of the HIV-1 virus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14592768     DOI: 10.1016/s0042-6822(03)00525-7

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  17 in total

1.  Structure of a V3-containing HIV-1 gp120 core.

Authors:  Chih-chin Huang; Min Tang; Mei-Yun Zhang; Shahzad Majeed; Elizabeth Montabana; Robyn L Stanfield; Dimiter S Dimitrov; Bette Korber; Joseph Sodroski; Ian A Wilson; Richard Wyatt; Peter D Kwong
Journal:  Science       Date:  2005-11-11       Impact factor: 47.728

2.  Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor.

Authors:  Dirk M Zajonc; Carlos Cantu; Jochen Mattner; Dapeng Zhou; Paul B Savage; Albert Bendelac; Ian A Wilson; Luc Teyton
Journal:  Nat Immunol       Date:  2005-07-10       Impact factor: 25.606

3.  Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.

Authors:  Kausik Chakraborty; Venuka Durani; Edward Roshan Miranda; Michael Citron; Xiaoping Liang; William Schleif; Joseph G Joyce; Raghavan Varadarajan
Journal:  Biochem J       Date:  2006-11-01       Impact factor: 3.857

4.  Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization.

Authors:  Christian H Bell; Ralph Pantophlet; André Schiefner; Lisa A Cavacini; Robyn L Stanfield; Dennis R Burton; Ian A Wilson
Journal:  J Mol Biol       Date:  2007-11-13       Impact factor: 5.469

5.  Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.

Authors:  Ralph Pantophlet; Rowena O Aguilar-Sino; Terri Wrin; Lisa A Cavacini; Dennis R Burton
Journal:  Virology       Date:  2007-04-06       Impact factor: 3.616

6.  Fold recognition of the human immunodeficiency virus type 1 V3 loop and flexibility of its crown structure during the course of adaptation to a host.

Authors:  Teruaki Watabe; Hirohisa Kishino; Yoshiyasu Okuhara; Yasuhiro Kitazoe
Journal:  Genetics       Date:  2005-12-15       Impact factor: 4.562

7.  Structure determination of an anti-HIV-1 Fab 447-52D-peptide complex from an epitaxially twinned data set.

Authors:  Amandeep K Dhillon; Robyn L Stanfield; Miroslaw K Gorny; Constance Williams; Susan Zolla-Pazner; Ian A Wilson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2008-06-18

8.  An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120.

Authors:  Adi Moseri; Subramanyam Tantry; Yael Sagi; Boris Arshava; Fred Naider; Jacob Anglister
Journal:  Virology       Date:  2010-03-26       Impact factor: 3.616

9.  Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247.

Authors:  Karen A Kirby; Yee Tsuey Ong; Atsuko Hachiya; Thomas G Laughlin; Leslie A Chiang; Yun Pan; Jennifer L Moran; Bruno Marchand; Kamalendra Singh; Fabio Gallazzi; Thomas P Quinn; Kazuhisa Yoshimura; Toshio Murakami; Shuzo Matsushita; Stefan G Sarafianos
Journal:  FASEB J       Date:  2014-10-28       Impact factor: 5.191

Review 10.  Molecular mechanisms of FIV infection.

Authors:  John H Elder; Magnus Sundstrom; Sohela de Rozieres; Aymeric de Parseval; Chris K Grant; Ying-Chuan Lin
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.